Venom Supplies recombinant toxins bridge the gap between natural diversity and manufacturing consistency. Utilizing microbial and mammalian expression platforms, we deliver correctly folded toxins, domains, and chimeric constructs that retain the pharmacological selectivity of their native counterparts. Each production run incorporates affinity purification, size-exclusion polishing, and oxidative folding protocols validated by circular dichroism and bioactivity assays.
Expression platforms tuned for activity
We employ Pichia pastoris, HEK293, and insect cell systems depending on disulfide complexity and post-translational requirements. Constructs such as recombinant α-bungarotoxin and ω-conotoxin MVIIA display binding affinities within 10% of native standards, supported by RLUs from fluorescence polarization or radioligand displacement assays. Cofactor and glycosylation states are documented to inform downstream application compatibility.
Engineered fragments and fusion tags
Discovery teams often require truncated toxin domains to probe binding epitopes or develop neutralizing antibodies. Venom Supplies designs fragments with flexible linkers, His-tags, or Fc-fusions to facilitate purification and assay integration. Each listing specifies residue boundaries, tag configuration, and cleavage options. These materials are cross-referenced within the Receptor Pharmacology and Neuroscience application narratives to illustrate experimental deployments.
Regulatory-grade documentation
Recombinant lots include COAs covering purity, endotoxin (< 0.1 EU/μg), host cell protein (HCP) levels, and residual DNA quantitation. Stability studies simulate multiple freeze–thaw cycles, with activity retention plotted over six months. SDS files outline biosafety handling and decontamination guidance aligned with institutional biosafety committee expectations. For IND-enabling studies, we offer extended characterization packages under quality agreements.
Linked resources
- Sample catalog entries: PTX-RCT-001 Recombinant α-bungarotoxin, PTX-RCT-004 ω-conotoxin MVIIA recombinant, and PTX-RCT-008 PLA2 catalytic domain.
- Recommended deep dives include the Quality & Compliance framework and the blog article From venom to therapeutic lead: an overview for researchers.
- Request custom expression projects or scale-up manufacturing support via the Contact or Support channels.
Venom Supplies recombinant toxins provide scalable, reproducible bioactivity for screening campaigns, assay standards, and translational pharmacology initiatives.